Telix Reports Third Quarter 2022 Financial Results
MELBOURNE, Australia, Oct. 19, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quar...
Source: businessinsider.com
📰 Expanded Access Program News
Page 13 - Expanded Access Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Expanded Access Program. Real-time updates on events, politics, business and more.
Telix Reports Third Quarter 2022 Financial Results
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying...
Source: prnewswire.com
Telix Reports Third Quarter 2022 Financial Results
/PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today issues its Appendix 4C quarterly cash flow statement and accompanying...
Source: prnewswire.com
Albireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHAN
– New data presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition meeting – Earlier treatment with Bylvay provided greater efficacy in... | October 13, 2022
United States United Kingdom Vastra Gotalands Lan Northern Ireland Mecklenburg Vorpommern Colleen Alabiso
Source: marketscreener.com
Albireo Pharma, Inc.: Albireo Reports Positive Topline Data from Phase 3 Trial of Bylvay (odevixibat) in Alagille Syndrome
Highly statistically significant improvement in pruritus primary endpoint (p=0.002)Significant reductions in key secondary endpoint of serum bile acid levels (p=0.001)Substantial improvements in multiple
Source: finanznachrichten.de
Albireo to Showcase New Data at AASLD The Liver Meeting®
– Seven abstracts accepted, including one oral presentation highlighting long-term data demonstrating Bylvay® (odevixibat) durable efficacy in patients...
Source: globenewswire.com
Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)
- ACT for ALS Funding is for an Expanded Access Program to Study SLS-005 in Amyotrophic Lateral Sclerosis Patients Who Do Not Qualify for Clinical Trials NEW YORK, Sept. 30, 2022 /PRNewswire/ --... | September 30, 2022
Source: marketscreener.com
AIM ImmunoTech to Present at the Virtual Investor Long
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of...
Source: globenewswire.com
AIM ImmunoTech to Present at the Virtual Investor Long COVID Event
21.09.2022 - Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at ...
Source: wallstreet-online.de
Cardiff Oncology (NASDAQ:CRDF) – Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 - Press Release
Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Phase 1b/2 clinical trial of onvansertib plus FO
Source: wiredprnews.com